Biomedical or Dental Material
Bristol Myers Squibb Terminates $1.6 Billion Deal, Returns TIGIT Rights to Agenus
Bristol Myers Squibb, Agenus, TIGIT, licensing agreement, pharmaceutical deal
Otsuka Pharmaceutical Acquires Jnana Therapeutics for $800M to Develop PKU Treatment
Otsuka Pharmaceutical, Jnana Therapeutics, PKU, phenylketonuria, JNT-517, RAPID chemoproteomics platform, rare metabolic disorder, biotech acquisition
President Biden Highlights Achievements in Lowering Prescription Drug Costs as He Steps Down from Re-election Campaign
President Biden, drug pricing, re-election campaign, Medicare, Inflation Reduction Act, prescription drug costs, health care costs, pharmaceutical industry
Novartis Partners with Dren Bio in $3 Billion Deal for Targeted Myeloid Engagers
Novartis, Dren Bio, Myeloid Engagers, Biotech, Pharmaceutical, Alliance, $3 Billion Deal
Ionis Advances to Phase 3 Trial for Angelman Syndrome Treatment ION582
Ionis Pharmaceuticals, Angelman syndrome, ION582, Phase 3 trial, antisense oligonucleotides, neurological conditions, rare diseases, Biogen, Ultragenyx Pharmaceutical
How the world’s biggest pharma and biotech companies paid their typical worker in 2023
Dosage Forms, Industry, world ‘s, Worker, 2023
Medical Devices Outshine Rx Drugs at Cannes Lions, Highlighting Shift in Customer Focus
Cannes Lions, Medical Devices, Rx Drugs, Customer Focus, Jury President
FDA Approves Tris Pharma’s Onyda XR, First Liquid Non-Stimulant ADHD Medication for Pediatric Patients ###
Tris Pharma, Onyda XR, ADHD, Non-stimulant, Liquid medication, Pediatric patients, FDA approval, Clonidine hydrochloride, Extended-release oral suspension, LiquiXR technology
EMA Recommends Halt on Preterm Birth Medications Due to Safety Concerns
European Medicines Agency (EMA), safety committee, preterm birth drugs, suspension, safety concerns, pregnancy, fetal development.
Europe Temporarily Halts AstraZeneca’s Vaxzevria COVID-19 Vaccine on Company’s Request
AstraZeneca, Vaxzevria, COVID-19 vaccine, marketing authorization, suspension, Europe, European Medicines Agency (EMA), pharmacovigilance, safety concerns.